Literature DB >> 283266

Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose.

O Stutman.   

Abstract

The incidence and latency periods for local tumor development after sc injection of 3-methylcholanthrene (MCA) into 30-day-old nude mice (nu/nu partially inbred on the CBA/H background) derived from homozygous matings (nu/nu times nu/nu) or heterozygous matings (nu/+ times nu/+) were comparable and did not differ with the immunologically normal controls, even when the carcinogen dosages ranged from 0.01 to 0.10 mg. Similarly, no differences in tumor incidence or latency periods between nude mice from homozygous or heterozygous matings as well as their immunologically normal controls were observed when weight-adjusted doses of MCA equivalent to 0.02 to 0.10 mg in the 30-day-old mice were administered at 120, 210, or 360 days of age. Tumor incidence was lower in nude mice and normal mice when MCA was administered at 210 and 360 days of age, especially in mice given the lower dose of MCA. The lower dosages of MCA (0.01-0.05 mg) had no detectable immunodepressive effects in normal mice. Thus the "normal" tumor incidence in nude mice after MCA administration could not be attributed to: 1) the effect of humoral thymus gland function (in the nude mice derived from heterozygous matings), 2) the immunodepressive effects of the carcinogen (the lower MCA dosages are not immunodepressive), or 3) the age of the mice at administration. These results argue against the thymus dependency of immunologic surveillance.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 283266

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  25 in total

Review 1.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  The importance of animal models in tumor immunity and immunotherapy.

Authors:  Sadna Budhu; Jedd Wolchok; Taha Merghoub
Journal:  Curr Opin Genet Dev       Date:  2013-12-29       Impact factor: 5.578

Review 3.  Improving T cell responses to modified peptides in tumor vaccines.

Authors:  Jonathan D Buhrman; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

Review 4.  The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

Authors:  Jeffrey P Ward; Matthew M Gubin; Robert D Schreiber
Journal:  Adv Immunol       Date:  2016-02-10       Impact factor: 3.543

5.  Tolerance and immune suppression in the tumor microenvironment.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cell Immunol       Date:  2015-09-30       Impact factor: 4.868

6.  A model of the role of natural killer cells in immune surveillance--II.

Authors:  S J Merrill
Journal:  J Math Biol       Date:  1983       Impact factor: 2.259

7.  Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.

Authors:  Shanjin Cao; Zhaoying Xiang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2004-10       Impact factor: 11.530

8.  Lack of a relationship between immune function and chemically induced hepatocarcinogenesis in B6C3F1 mice.

Authors:  D R Germolec; R R Maronpot; M F Ackermann; S J Vore; K Dittrich; G J Rosenthal; M I Luster
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Incidence and growth of methylcholanthrene-induced tumors in mice with altered immunological status.

Authors:  C Trutin-Ostović; M Golubić; M Matović; M Marusić
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Comparison of dose-dependent enhancing effects of gamma-ray irradiation on urethan-induced lung tumorigenesis in athymic nude (nu/nu) mice ac (nu/+) littermates.

Authors:  S Kobayashi; H Otsu; Y Noda; T Ogiu
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.